The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

January 1, 2027

Study Completion Date

December 31, 2027

Conditions
Diabetes ComplicationsDiabetes; Nephropathy (Manifestation)
Interventions
DRUG

Roxadustat

"The group will receive Roxadustat (Evrenzo) three times weekly at an initial dose of 70mg (for body weight \<100.0 kg) or 100 mg (for body weight weight ≥100.0 kg). The dosage for both arms will be adjusted to keep Hb at the recommended levels between 11-12g/dl.~The aim is to investigate the effects of systemic administration of Evrenzo (Roxadustat \[RD\]) or Aranesp (darbepoetin alpha \[DA\]) on the levels of renal oxygenation in patients with diabetic nephropathy and associated anemia."

DRUG

Darbepoietin Alfa

"The control group will receive darbepoietin alpha (Aranesp) s.c. 0.45mg/kg once a week. The dosage for both arms will be adjusted to keep Hb at the recommended levels between 11-12g/dl.~The aim is to investigate the effects of systemic administration of Evrenzo (Roxadustat \[RD\]) or Aranesp (darbepoetin alpha \[DA\]) on the levels of renal oxygenation in patients with diabetic nephropathy and associated anemia."

Trial Locations (1)

Unknown

Centre for diabetes, Stockholm

All Listed Sponsors
lead

Region Stockholm

OTHER_GOV